For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
After only one week since publishing of the first version on 20-Mar-2020, an updated version 2 of “The guidance on the management of clinical trials during COVID-19 (Coronavirus) pandemic” has been published on the European Commission’s website EudraLex Volume 10.
In version 2 new sections addressing the safety reporting, the distribution of in vitro diagnostic and medical devices, and to auditing clinical trials have been added, while other sections such as for obtaining the informed consent have been enhanced with further clarification or expanded with additional aspects.
In the newly added section on safety reporting it is re-stated that safety reporting should continue to adhere to EU legal framework and implementing national legislations. However, it is also emphasized that investigators should seek alternatives to collect adverse events from trial subjects in those cases “where per protocol physical visits are reduced or postponed”.
Further details within the EU legislation framework have been added for obtaining the informed consent of trial subjects with COVID-19 infection and resulting physical isolation and where they “lack capacity to consent due to the severity of their medical condition”.
Relevant for new clinical trials is the addition made, that the risk-benefit section in the protocol should address additional risks to the trial subjects along with risk mitigation measures for new clinical trials and reference to further details is then made to the section “risk assessment”.
The guidance remains a set of recommendations to manage clinical trials under the COVID-19 pandemic within the European Union, recognizing that applicable national rules (legislations or guidance) may take precedence. On the other hand, its joint issuing by the European Commission, the European Medicines Agency (EMA), the Clinical Trials Facilitation and Coordination Group (CTFG) of the Heads of Medicines Agencies (HMA), and the Clinical Trials Expert Group (CTEG) of the European Commission, provides relevant stakeholders (sponsors, CROs, investigators) the most harmonized approach for clinical trials within the EU legislation framework.
Population diversity: important considerations in vaccine development
Jun 14, 2023
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Master Protocols from Design to Delivery
Sep 30, 2021
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021